Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024Business Wire • 05/01/24
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail TherapeuticsBusiness Wire • 04/16/24
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?Zacks Investment Research • 04/11/24
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.Business Wire • 04/04/24
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should KnowZacks Investment Research • 04/02/24
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 04/02/24
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/27/24
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business UpdateBusiness Wire • 03/27/24
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024Business Wire • 03/20/24
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial MyopathyBusiness Wire • 03/19/24
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC DeficiencyBusiness Wire • 03/06/24
Precision BioSciences Announces $40.0 Million Offering of Common Stock and WarrantsBusiness Wire • 03/01/24
Precision BioSciences Announces Proposed Public Offering of Common Stock and WarrantsBusiness Wire • 02/29/24
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?Zacks Investment Research • 02/27/24
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou BiosciencesBusiness Wire • 02/20/24
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical ReadinessBusiness Wire • 02/14/24
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor RelationsBusiness Wire • 02/13/24
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune DiseasesBusiness Wire • 02/12/24
TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseasesMarket Watch • 01/10/24
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune DiseasesBusiness Wire • 01/09/24
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECUREBusiness Wire • 12/13/23
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial DiseasesBusiness Wire • 12/04/23
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 11/28/23